SCYX stock forecast
Our latest prediction for SCYNEXIS, Inc.'s stock price was made on the Aug. 21, 2019 when the stock price was at 1.11$.
In the short term (2weeks), SCYX's stock price should outperform the market by 5.80%. During that period the price should oscillate between -6.60% and +14.55%.
In the medium term (3months), SCYX's stock price should outperform the market by 8.83%. During that period the price should oscillate between -15.31% and +38.62%.Get email alerts
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.68$ per share.
The book value per share is 0.56$
Three months stock forecastAug. 21, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|